Potential CRF1R PET imaging agents: N-Fluoroalkyl-8-(6-methoxy- 2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-amines

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2484-2488

  Zuev, Dmitry ^a   Mattson, Ronald J ^a   Huang, Hong ^a   Mattson, Gail K ^a   Zueva, Larisa ^b   Nielsen, Julia M ^b   Kozlowski, Edward S ^a   Huang, Xiaohua Stella ^a   Wu, Dedong ^a   Gao, Qi ^a   Lodge, Nicholas J ^a   Bronson, Joanne J ^a   MacOr, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Spectrix Analytical Services   (United States)

Author keywords

Anxiety; Corticotropin releasing factor; Depression; Imaging agents; Positron emission tomography

Indexed keywords

ALKYL GROUP; AMINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; FLUORENE DERIVATIVE; OCTANOL; PHOSPHATE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TRIAZINE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; DIAGNOSTIC AGENT;

ARTICLE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; IC 50; LIPOPHILICITY; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; CHEMISTRY; CONFORMATION; METABOLISM; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

AMINES; CRYSTALLOGRAPHY, X-RAY; MOLECULAR CONFORMATION; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRIAZINES;

EID: 79953278002     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.050     Document Type: Article

References (26)

1. M. Owens, and C.B. Nemeroff Pharmacol. Rev. 43 1991 425
2. D.E. Grigoriadis, M. Haddach, N. Ling, and J. Saunders Curr. Med. Chem., CNS Agents 1 2001 63
3. P.M. Plotsky J. Neuroendocrinol. 3 1991 1
4. C.M. Banki, L. Karmasci, G. Bissette, and C.B. Nemeroff Eur. Neuropsychopharmacol. 2 1992 107
5. F. Holsboer J. Psychiatric Res. 33 1999 181
6. J.W. Kaskow, D. Baker, and T.D. Geracioti Peptides 22 2001 845
7. L.K. Takahashi Neurosci. Behav. Rev. 25 2001 627
8. C.D. Dzierba, R.A. Hartz, and J.J. Bronson Annu. Rep. Med. Chem. 43 2008 3
9. P.J. Gilligan, D.W. Robertson, and R. Zaczek J. Med. Chem. 43 2000 1641
10. L.-W. Hsin, E.L. Webster, G.P. Chrousos, P.W. Gold, W.C. Eckelman, C. Contoreggi, and K.C. Rice Bioorg. Med. Chem. Lett. 10 2000 707
11. L. Martarello, C.D. Kilts, T. Ely, M.J. Owens, C.H. Nemeroff, M. Camp, and M.M. Goodman Nucl. Med. Biol. 28 2001 187
12. E. Jagoda, C. Contoreggi, M.-J. Lee, C.-H.K. Kao, L.P. Szajek, S. Listwak, P. Gold, G. Chrousos, E. Greiner, B.M. Kim, A.E. Jacobson, K.C. Rice, and W. Eckelman J. Med. Chem. 46 2003 3559
13. J.S. Dileep Kumar, V.J. Majo, G.M. Sullivan, J. Prabhakaran, N.R. Simpson, R.L. Van Heertum, J.J. Mann, and R.V. Parsey Bioorg. Med. Chem. 14 2006 4029
14. G.M. Sullivan, R.V. Parsey, J.S. Dileep Kumar, V. Arango, S.A. Kassir, Y. Huang, N.R. Simpson, R.L. Van Heertum, and J.J. Mann Nucl. Med. Biol. 34 2007 353
15. P.J. Gilligan, T. Clarke, L. He, S. Lelas, Y.-W. Li, K. Heman, L. Fitzgerald, K. Miller, G. Zhang, A. Marshall, C. Krause, J.F. McElroy, K. Ward, K. Zeller, H. Wong, S. Bai, J. Saye, S. Grossman, R. Zaczek, P. Hartig, D. Robertson, and G. Trainor J. Med. Chem. 52 2009 3084
16. Gilligan, P. J. 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid- 3-yl)[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as a corticotropin releasing factor Receptor ligands, US 7157578 B2 (2007).
17. 2O (10%)/TFA (0.1%); starting% B, 0; final% B, 100; flow rate 5 mL/min; gradient time, 2 min; end time, 3 min.
18. G.M. Dubowchik, J.A. Michne, and D. Zuev Bioorg. Med. Chem. Lett. 14 2004 3147
19. 125I-o-CRF (2200 Ci/mmol) was obtained from PerkinElmer Life Sciences, Inc. (Boston, MA).
20. Shake-flask log D determination assay for lipophilicity: In a 250 mL separatory funnel were added 25 mM phosphate buffer (200 mL) and octanol (10 mL). The two-phase system was mixed well and let stand overnight to allow complete saturation and separation of both layers. A sample (1.0 mg) was dissolved in octanol (1 mL) and transferred to a volumetric flask, containing 50 mL of the phosphate buffer, saturated with octanol, as described above. The resulting mixture was shaken intensely for 30-40 min and was allowed to stand until two layers separated completely. A sample of each layer was analyzed by an HPLC method twice. The sample area counts were used to calculate the shake-flask log D.
21. +).
22. 2O (10%)/TFA (0.1%); starting% B, 30; final% B, 100; flow rate 25 mL/min; gradient time, 20 min; end time, 25 min.
23. E.-L. Kämäräinen, T. Kyllönen, A. Airaksinen, C. Lundkvist, M. Yu, K. Ngren, J. Sandell, O. Langer, J. Vepsäläinen, J. Hiltunen, K. Bergström, S. Lötjönen, T. Jaakkola, and C. Halldin J. Labelled Compd. Radiopharm. 37 1995 55
24. The X-ray crystal structure of 18 was deposited with Cambridge Crystallographic Data Centre (deposition number - CCDC 810575).
25. R.F. Heck Palladium Reagents in Organic Synthesis 1987 Academic London
26. The log D values of compounds 1-6 had not been reported and, therefore, were unavailable for comparison with the log D value of 7e.